Recent quotes:

Continuous glucose monitoring to improve health in non-diabetics

For instance, in the Hall et al. study cited above, those with a glucotype associated with the largest fluctuations in blood glucose – roughly 24% of all normoglycemic participants tested – were found to spend roughly 15% of their time (over a 2-4 week test period) with glucose levels exceeding the threshold for prediabetes, demonstrating how even those considered metabolically healthy can have subclinical metabolic dysregulation that would likely be missed by a one-time blood glucose measurement.

Ultra-precision medicine | Nature Biotechnology

A Comment in this issue describes n-Lorem, an ambitious not-for-profit initiative with a mission to discover individualized experimental antisense oligonucleotide (ASO) treatments for patients with ultra-rare conditions arising from a single, often de novo, mutation (for example, an indel, repeat or single point mutation). Since its founding last year, n-Lorem has built a network of public–private partnerships with Ionis Pharmaceuticals, Biogen, Ultragenyx, Charles River Laboratories, Covance, the Korea Institute of Toxicology and the US National Institutes of Health’s Undiagnosed Disease Network to discover and develop individualized ASO drugs collaboratively with clinical investigators in academic medical centers.